Dallah Healthcare Company announces recent developments to the sale of its shares in Dr. Mohammed Bin Rashed Al Fagih & Partners Company for a value of SAR 497,983,407

Element List	Explanation
Introduction	With reference to the announcement made by Dallah Healthcare Company (“Dallah Healthcare”) on the Saudi Exchange website on 19/11/1447H (corresponding to 06/05/2026G) regarding the entry into a binding share sale and purchase agreement with Dr. Soliman Abdel Kader Fakeeh Hospital Co. (the “Buyer” or “Soliman Fakeeh Co.”) to sell Dallah Healthcare’s entire shareholding of approximately 31.21% in Dr. Mohammed bin Rashid Al Fagih & Partners Company (the “Target” or “Mohammed AlFagih Co.”) (the “Transaction”); Dallah Healthcare is pleased to announce the issuance of the non-objection of the General Authority for Competition on the completion of the economic concentration resulting from the Transaction on 25/12/1447H (corresponding to 11/06/2026G). The Transaction remains subject to a number of other conditions precedent. Dallah Healthcare will make an announcement when the Transaction completes, and when material developments occur in relation to the Transaction.
Previous Announcement	Dallah Healthcare Company announces the sale of its shares in Dr. Mohammed Bin Rashed Al Fagih & Partners Company for a value of SAR 497,983,407.
Date of Previous Announcement on Saudi Exchange’s Website	2026-05-06 Corresponding to 1447-11-19
Hyperlink to the Previous Announcement on the Saudi Exchange Website	Click Here
Latest Developments Of The Announced Event	The issuance of the non-objection of the General Authority for Competition on the completion of the economic concentration resulting from the Transaction.
Reasons For The Delay on The Date of The Event Previously Announced	Not Applicable.
The costs associated with the event, and if they have changed or not with indication of the reasons.	Not Applicable.
Delay consequences on the Company’s financial results	Not Applicable.